Verdict for J&J Upheld in Patent Suit Over Schizophrenia Drug

A trial win by Johnson & Johnson’s Janssen unit in a patent infringement suit over its blockbuster schizophrenia drug, Invega Sustenna, will stand against Tolmar Inc., a federal judge ruled.

Finding none of Tolmar’s arguments “persuasive,” Judge William C. Bryson of the US District Court for the District of Delaware denied Tolmar’s motion for reconsideration of his bench trial ruling that the patent was valid. Tolmar had conceded infringement of the patent before trial.

Bryson rejected Tolmar’s argument that an April ruling of the US Court of Appeals for the Federal Circuit in a related case, issued after the verdict, ...